: IDEAYA Biosciences started at hold with $27 stock price target at Stifel Nicolaus

1 BUSINESS

Business News - Opportunities - Reviews

 

 

IDEAYA Biosciences Inc.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply